Mesenchymal Stem Cells: A Friend or Foe in Immune-Mediated Diseases

被引:0
|
作者
Marina Gazdic
Vladislav Volarevic
Nebojsa Arsenijevic
Miodrag Stojkovic
机构
[1] University of Kragujevac,Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences
[2] Spebo Medical,undefined
来源
Stem Cell Reviews and Reports | 2015年 / 11卷
关键词
Mesenchymal stem cells; Inflammation; Therapy; Immunosuppression; Autoimmunity;
D O I
暂无
中图分类号
学科分类号
摘要
Mesenchymal stem cells (MSCs) are adult, self-renewable, multipotent cells that can be found in almost all postnatal tissues. Because of their capacity for self-renewal and differentiation into tissues of mesodermal origin and due to their immunomodulatory ability, MSCs are used in many preclinical and clinical studies as possible new therapeutic agents for the autoimmune or degenerative diseases treatment. In dependence of inflammatory environment to which they are exposed to, MSCs adopt immunosuppressive or pro-inflammatory phenotype. In the presence of high levels of pro-inflammatory cytokines or through activation of Toll-like receptor (TLR)-3, MSCs adopt an immune-suppressive phenotype and suppress the proliferation, activation and effector function of professional antigen presenting cells (dendritic cells, macrophages, B lymphocytes), T lymphocytes, NK cells, NKT cells, and neutrophils. During the early phase of inflammation, through TLR4 activation and in the presence of low levels of inflammatory cytokines, MSCs adopt a pro-inflammatory phenotype, promote neutrophil and T cell activation and enhance immune response. Here we review the current findings on the immunoregulatory plasticity of MSCs involved in regulation of immune response.
引用
收藏
页码:280 / 287
页数:7
相关论文
共 50 条
  • [21] Role of immune regulatory cells in breast cancer: Foe or friend?
    Lan, Huan-Rong
    Du, Wen-Lin
    Liu, Yuyao
    Mao, Chun-Sen
    Jin, Ke-Tao
    Yang, Xue
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 96
  • [22] Mesenchymal stem cells and autoimmune diseases
    Dazzi, Francesco
    Krampera, Mauro
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2011, 24 (01) : 49 - 57
  • [23] Immune-mediated diseases II congress: Summary
    Shurin, Michael R.
    Smolkin, Yury S.
    JOURNAL OF IMMUNOTOXICOLOGY, 2008, 5 (02) : 159 - 162
  • [24] Obinutuzumab for the management of immune-mediated glomerular diseases
    Rossi, Giovanni M.
    Baier, Eva
    Vaglio, Augusto
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2025,
  • [25] Immune-Mediated Diseases Associated With Cancer Risks
    He, Ming-ming
    Lo, Chun-Han
    Wang, Kai
    Polychronidis, Georgios
    Wang, Liang
    Zhong, Rong
    Knudsen, Markus D.
    Fang, Zhe
    Song, Mingyang
    JAMA ONCOLOGY, 2022, 8 (02) : 209 - 219
  • [26] Mucosal-associated invariant T cells in autoimmunity, immune-mediated diseases and airways disease
    Hinks, Timothy S. C.
    IMMUNOLOGY, 2016, 148 (01) : 1 - 12
  • [27] Systemic Immune-Mediated Diseases and Dilated Cardiomyopathy
    Hershberger, Ray E.
    Ni, Hanyu
    JACC-HEART FAILURE, 2025, 13 (01) : 146 - 148
  • [28] Cell death in the pathogenesis of immune-mediated diseases
    Pisetsky, David S.
    SWISS MEDICAL WEEKLY, 2011, 141 : w13256
  • [29] Platelets in Rheumatic Diseases: Friend or Foe?
    Gasparyan, Armen Yuri
    Ayvazyan, Lilit
    Pretorius, Etheresia
    Kitas, George D.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (04) : 552 - 566
  • [30] The immune system in Duchenne muscular dystrophy: Friend or foe
    Villalta, S. Armando
    Rosenberg, Amy S.
    Bluestone, Jeffrey A.
    RARE DISEASES, 2015, 3 (01)